Key Steps in Precision Treatment: A Detailed Overview of CAR-T Infusion for a Russian Patient at Jiahui in Shanghai

Key Steps in Precision Treatment: A Detailed Overview of CAR-T Infusion for a Russian Patient at Jiahui in Shanghai**

Vladimir Borzenkov, a 68-year-old patient from St. Petersburg, Russia, recently completed the core phase of CAR-T therapy—reinfusion—at Jiahui International Hospital in Shanghai. This crucial step involves reinfusing T-cells, which have been genetically modified to recognize and attack specific cancer cells, back into the patient’s body. For Mr. Vladimir, who has been battling his condition for over five years, this step is particularly significant.

Before the reinfusion, the medical team conducted a comprehensive physical assessment to ensure his body could withstand the procedure. Despite being in his sixties, Vladimir’s determination and desire for a cure helped him overcome any obstacles posed by his age. His journey began in December 2017 with back pain, which progressively worsened over several months. By February 2018, multiple bones, including his spine, sternum, and clavicle, showed signs of deterioration. Although this period seemed like a relentless trial, Vladimir never lost his faith in life. Now, at this critical juncture, he is filled with hope for the future.

For this treatment, Jiahui Hospital utilized FUCASO (Eque-cel), a fully human CAR-T therapy known for its unique low immunogenicity and lasting efficacy, providing therapeutic advantages for the patient. During the reinfusion process, Jiahui Hospital demonstrated advanced capabilities in monitoring and managing adverse reactions. The hospital is equipped with the latest monitoring technology and a highly experienced medical team, ensuring that any potential adverse reactions are promptly identified and managed, thus ensuring the safety and effectiveness of the treatment. This high level of monitoring and detailed attention to the patient’s health made Vladimir’s treatment process not only efficient but also safe.

Through his experience at Jiahui International Hospital, Vladimir witnessed the powerful potential of CAR-T therapy and the significant advantages of FUCASO. He is now filled with hope for the future treatment outcomes. This treatment marks not only a significant milestone in his personal battle against cancer but also showcases Jiahui’s expertise in CAR-T technology and excellent patient care.

#CART #MultipleMyeloma #FUCASOJourney #Equecel #JiahuiHospital #Shanghai #CancerSurvivor #bloodcancer #Immunotherapy #FullyHumanCART #CancerTreatment

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

8 months ago CAR-T

Precision Treatment Journey: Defeating Multiple Myeloma with Chinese CAR-T Therapy

👑🍋Precision Treatment Journey: Defeating Multiple Myeloma with Chinese CAR-T Therapy👑🍋

Multiple Myeloma

 

💪Meet John, a resilient man from New Zealand who has been battling multiple myeloma, a relentless form of cancer. Severe bone pain has confined him to bed for an extended period, disrupting his daily life. However, a glimmer of hope emerged when he sought treatment at Renji Hospital’s Hematology Department in Shanghai, China.

🍒Renji Hospital’s medical team, led by Professor Hou Jian, specializes in CAR-T cell therapy, a revolutionary approach to target cancer cells with precision. John’s journey began eleven years ago when he was diagnosed with multiple myeloma. Despite undergoing numerous chemotherapy sessions and two autologous stem cell transplants, his condition deteriorated rapidly over the past year.

🍈Intense back pain rendered him unable to stand or walk, forcing him into prolonged bed rest and heavy reliance on pain medication. Further assessments revealed widespread extramedullary plasmacytomas in his bones and throat, along with complex chromosomal abnormalities, indicating a grim prognosis.

🍓Having exhausted conventional treatments, John explored alternative options and learned about Renji Hospital’s expertise in CAR-T cell therapy for refractory multiple myeloma. In 2016, Professor Hou Jian’s team initiated clinical trials utilizing CAR-T cell therapy, accumulating significant experience in treating relapsed and refractory cases.

🍇Upon evaluation, John’s medical team identified substantial tumor burden and compromised bone marrow function due to extensive chemotherapy. Despite the challenges, Professor Hou Jian’s team tailored a personalized treatment plan, opting for dual CAR-T therapy targeting CD19 and BCMA antigens.

🥑John has since returned to New Zealand and maintains regular contact with his medical team at Renji Hospital. Ongoing monitoring and follow-ups ensure his progress is closely tracked. “John is gradually reclaiming his daily life. Recently, he even shared photos of hiking and fishing adventures with us,” Professor Hou Jian shared.

🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

Email: doctor.huang@globecancer.com,

WhatsApp: +8613717959070

 

#CARTtherapy #MultipleMyeloma #PrecisionTreatment #RenjiHospital #HopeInHealthcare #CART #cancer #cancertreatment #medicaltourism #tuomor #cartcell #CARTtherapy